Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ENTX
Upturn stock ratingUpturn stock rating

Entera Bio Ltd (ENTX)

Upturn stock ratingUpturn stock rating
$1.9
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: ENTX (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

1 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $10

1 Year Target Price $10

Analysts Price Target For last 52 week
$10Target price
Low$1.41
Current$1.9
high$2.79

Analysis of Past Performance

Type Stock
Historic Profit 10.07%
Avg. Invested days 44
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 2.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 89.99M USD
Price to earnings Ratio -
1Y Target Price 10
Price to earnings Ratio -
1Y Target Price 10
Volume (30-day avg) 1
Beta 1.48
52 Weeks Range 1.41 - 2.79
Updated Date 06/29/2025
52 Weeks Range 1.41 - 2.79
Updated Date 06/29/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.26

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -6102.38%

Management Effectiveness

Return on Assets (TTM) -39.6%
Return on Equity (TTM) -71.46%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 77637745
Price to Sales(TTM) 403.55
Enterprise Value 77637745
Price to Sales(TTM) 403.55
Enterprise Value to Revenue 348.15
Enterprise Value to EBITDA -1.52
Shares Outstanding 45452200
Shares Floating 28901215
Shares Outstanding 45452200
Shares Floating 28901215
Percent Insiders 23.97
Percent Institutions 22.49

Analyst Ratings

Rating 1
Target Price 10
Buy 1
Strong Buy -
Buy 1
Strong Buy -
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Entera Bio Ltd

stock logo

Company Overview

overview logo History and Background

Entera Bio Ltd. is a clinical-stage biopharmaceutical company focused on developing orally delivered large molecule therapeutics for unmet medical needs. Founded to address challenges in oral peptide and protein delivery, they are developing novel formulations to enhance absorption.

business area logo Core Business Areas

  • Oral Peptide/Protein Delivery: Entera Bio is focused on developing and commercializing oral formulations of peptides and proteins, overcoming the challenges of gastrointestinal degradation and poor absorption associated with traditional injection-based therapies.
  • Osteoporosis Treatment: The company's primary focus is on developing oral parathyroid hormone (PTH) analogs for the treatment of osteoporosis and related bone disorders.

leadership logo Leadership and Structure

Entera Bio has a management team with experience in pharmaceutical development, regulatory affairs, and commercialization. Their organizational structure includes departments for research and development, clinical operations, and business development.

Top Products and Market Share

overview logo Key Offerings

  • EB613 (Oral PTH): EB613 is Entera Bio's lead product candidate, an oral formulation of parathyroid hormone (PTH) for the treatment of osteoporosis. It aims to provide a convenient alternative to injectable PTH therapies. EB613 is currently in clinical development, with ongoing studies to evaluate its efficacy and safety. There is no market share data available as this is still under development. Competitors include injectable PTH therapies such as Eli Lilly's Forteo and Radius Health's Tymlos.

Market Dynamics

industry overview logo Industry Overview

The osteoporosis treatment market is characterized by a growing prevalence of the disease due to an aging population. The market is competitive, with established injectable therapies and emerging oral formulations seeking to address patient needs and improve adherence.

Positioning

Entera Bio aims to differentiate itself by offering an oral alternative to injectable PTH therapies, which could improve patient convenience and compliance. Their competitive advantage lies in their proprietary oral delivery technology, which enables the absorption of large molecules through the gastrointestinal tract.

Total Addressable Market (TAM)

The global osteoporosis market is projected to reach billions of dollars. Entera Bio aims to capture a significant portion of this market by offering a convenient oral therapy. Currently, since there is no product commercialized, the TAM share is small.

Upturn SWOT Analysis

Strengths

  • Proprietary oral delivery technology
  • Potential for improved patient compliance
  • Experienced management team

Weaknesses

  • Limited financial resources
  • Clinical development risk
  • Dependence on a single lead product candidate

Opportunities

  • Growing osteoporosis market
  • Potential partnerships with larger pharmaceutical companies
  • Expansion into other therapeutic areas

Threats

  • Competition from established therapies
  • Regulatory hurdles
  • Generic erosion of existing treatments

Competitors and Market Share

competitor logo Key Competitors

  • LLY
  • RDUS

Competitive Landscape

Entera Bio competes with established pharmaceutical companies that market injectable osteoporosis therapies. Its advantage lies in the potential for oral delivery, but faces challenges related to clinical development and regulatory approval.

Growth Trajectory and Initiatives

Historical Growth: Historical growth has been characterized by preclinical and clinical development milestones. Investors assess the company's progress based on the advancement of its lead product candidate through clinical trials.

Future Projections: Future growth is dependent on the successful completion of clinical trials and regulatory approval of EB613. Analyst estimates vary depending on the perceived probability of success and market potential.

Recent Initiatives: Recent initiatives include ongoing clinical trials of EB613, presentations at scientific conferences, and efforts to secure partnerships and funding.

Summary

Entera Bio is a clinical-stage biopharmaceutical company focused on oral delivery of large molecules, primarily for osteoporosis treatment. While their proprietary technology presents a potential advantage, they face significant clinical development risks and competition from established therapies. Their success hinges on positive clinical trial results for EB613. The company needs to continue securing funding to advance its clinical programs.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company SEC filings
  • Analyst reports
  • Company presentations

Disclaimers:

This analysis is for informational purposes only and should not be considered investment advice. Please consult with a qualified financial advisor before making any investment decisions. Market share data is estimated and may not be precise. Financial data is as of the latest available information from public sources.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Entera Bio Ltd

Exchange NASDAQ
Headquaters -
IPO Launch date 2018-06-28
CEO & Director Ms. Miranda J. Toledano M.B.A.
Sector Healthcare
Industry Biotechnology
Full time employees 18
Full time employees 18

Entera Bio Ltd., a clinical stage company, focuses on developing oral peptide or protein replacement therapies for unmet medical needs. The company leverages its N-Tab platform that is designed to simultaneously stabilize the peptide in the gastrointestinal tract and promote its absorption into the bloodstream. It also develops EB613, an oral PTH (1-34), that has completed Phase 2 clinical trial for the treatment of post-menopausal women with low bone mineral density and high-risk osteoporosis; and has completed Phase 1 clinical trial to treat stress fractures. In addition, the company is developing EB612, a tablet peptide replacement therapy for hypoparathyroidism. Further, it develops oral oxyntomodulin (OXM), a dual targeted GLP1/glucagon peptide, in tablet form for the treatment of obesity and metabolic disorders; and GLP-2 peptide tablet as an injection-free alternative for patients suffering from rare malabsorption conditions, such as short bowel syndrome. The company has research collaboration agreement with OPKO Biologics, Inc. Entera Bio Ltd. was incorporated in 2009 and is headquartered in Jerusalem, Israel.